Haleon Pakistan Limited (HALEON): Growth Boost from New Launches and Lower Costs
Haleon Pakistan Limited (HALEON), the well-known consumer healthcare company, is on track for a strong performance in 2QCY25. The company is expected to post earnings...
Are Pharma Stocks in Pakistan Poised for a Rerating?
After years of navigating tight price controls, rising costs, and volatile exchange rates, Pakistan’s pharmaceutical sector appears to be at a critical inflection point. Thanks...
Why pharma exports could be Pakistan’s next billion-dollar opportunity?
Pakistan’s pharmaceutical industry has been on an upward trajectory thanks to deregulation, margin expansion, and a rising domestic market. But a far less discussed, and...
Pharma Stock Valuations Are at a Discount, Is Now the Time to Buy?
Pakistan’s pharmaceutical sector has quietly morphed into a compelling value play. Despite major regulatory relief, margin expansion, and earnings growth, valuations across the board remain...
Can Pakistan’s local drugmakers outperform multinationals?
Pakistan’s pharmaceutical sector has entered a phase of structural transformation, and one question stands out: Can local drug manufacturers truly outperform multinational companies (MNCs)? Based...
Is Haleon stock ready to soar on new Panadol variants?
In Pakistan’s evolving pharmaceutical landscape, few brands hold as dominant a position as Panadol. Now, Haleon Pakistan Ltd (HALEON) is doubling down on this flagship...
Pharma sector earnings rise, valuations fall: is it a buying opportunity?
The pharmaceutical sector in Pakistan delivered a strong performance in 1QCY25, with listed companies showing robust profitability driven by favorable macro and regulatory developments. Using...